Therapeutic Human Cells: Manufacture for Cell Therapy/Regenerative Medicine

Cell therapy is a key tool of regenerative medicine, but until the beginning of the last decade, products based on viable human cells were used primarily to repair damaged tissues and organs. Currently, the field of application of biomedical cell products has expanded significantly, but researchers still show considerable interest in the use of human cells in regenerative medicine. The stage of development of cell products varies significantly depending on the type of tissue and pathology, and ranges from preclinical and pilot clinical trials to authorised drugs with a long history of use. On the one hand, this may be attributed to methodological differences in the production and use of cell products, and on the other, to specific aspects of differentiation of cell types used in regenerative medicine, primarily mesenchymal stem cells. The aim of this study was to analyse current trends in the use of cell therapy in regenerative medicine and prospects for using available technologies. The paper summarises the main achievements in the use of cell therapy for regeneration of skin, bone and cartilage, nervous and cardiovascular systems. The key mechanisms of cell therapy effect are determined, on the one hand, by the differentiation potential of multipotent cells, and on the other, by the complex (immunomodulating, angiogenic, proliferative) action of the proteome expressed by the administered cells. The paper describes viable cell-based products currently authorised for each indication, and analyses the level of their clinical use. It might be promising to use directed cell differentiation technologies, as well as induced pluripotent cells in regenerative medicine.

Download Full-text

Sous la direction de Jean-François Stoltz — Regenerative Medicine and Cell Therapy — Édité par Jean-François Stoltz (Nancy) — IOS Press — Biomedical and Health Research, 446 pages, 2012

Bulletin de l Académie Nationale de Médecine ◽

10.1016/s0001-4079(19)31637-1 ◽

2013 ◽

Vol 197 (1) ◽

pp. 191-192

Author(s):

Jacques Caen

Keyword(s):

Regenerative Medicine ◽

Cell Therapy ◽

Health Research

Download Full-text

iPSC technology-based regenerative medicine for kidney diseases

Clinical and Experimental Nephrology ◽

10.1007/s10157-021-02030-x ◽

2021 ◽

Author(s):

Kenji Osafune

Keyword(s):

Regenerative Medicine ◽

Cell Therapy ◽

Kidney Development ◽

Disease Modeling ◽

Kidney Diseases ◽

Collecting Duct ◽

Current Status ◽

Renal Tubules ◽

Discovery Research ◽

Drug Discovery Research

AbstractWith few curative treatments for kidney diseases, increasing attention has been paid to regenerative medicine as a new therapeutic option. Recent progress in kidney regeneration using human-induced pluripotent stem cells (hiPSCs) is noteworthy. Based on the knowledge of kidney development, the directed differentiation of hiPSCs into two embryonic kidney progenitors, nephron progenitor cells (NPCs) and ureteric bud (UB), has been established, enabling the generation of nephron and collecting duct organoids. Furthermore, human kidney tissues can be generated from these hiPSC-derived progenitors, in which NPC-derived glomeruli and renal tubules and UB-derived collecting ducts are interconnected. The induced kidney tissues are further vascularized when transplanted into immunodeficient mice. In addition to the kidney reconstruction for use in transplantation, it has been demonstrated that cell therapy using hiPSC-derived NPCs ameliorates acute kidney injury (AKI) in mice. Disease modeling and drug discovery research using disease-specific hiPSCs has also been vigorously conducted for intractable kidney disorders, such as autosomal dominant polycystic kidney disease (ADPKD). In an attempt to address the complications associated with kidney diseases, hiPSC-derived erythropoietin (EPO)-producing cells were successfully generated to discover drugs and develop cell therapy for renal anemia. This review summarizes the current status and future perspectives of developmental biology of kidney and iPSC technology-based regenerative medicine for kidney diseases.

Download Full-text

Cell Therapy and Bioengineering in Experimental Liver Regenerative Medicine: In Vivo Injury Models and Grafting Strategies

Current Transplantation Reports ◽

10.1007/s40472-021-00325-2 ◽

2021 ◽

Author(s):

G. Amato ◽

T. Saleh ◽

G. Carpino ◽

E. Gaudio ◽

D. Alvaro ◽

...

Keyword(s):

Regenerative Medicine ◽

Cell Therapy ◽

Cell Delivery ◽

Effective Strategies ◽

Multiple Strategies ◽

End Stage ◽

Therapy Strategies ◽

Injury Models ◽

Experimental Liver

Abstract Purpose of Review To describe experimental liver injury models used in regenerative medicine, cell therapy strategies to repopulate damaged livers and the efficacy of liver bioengineering. Recent Findings Several animal models have been developed to study different liver conditions. Multiple strategies and modified protocols of cell delivery have been also reported. Furthermore, using bioengineered liver scaffolds has shown promising results that could help in generating a highly functional cell delivery system and/or a whole transplantable liver. Summary To optimize the most effective strategies for liver cell therapy, further studies are required to compare among the performed strategies in the literature and/or innovate a novel modifying technique to overcome the potential limitations. Coating of cells with polymers, decellularized scaffolds, or microbeads could be the most appropriate solution to improve cellular efficacy. Besides, overcoming the problems of liver bioengineering may offer a radical treatment for end-stage liver diseases.

Download Full-text

Regenerative medicine and traumatic brain injury: from stem cell to cell-free therapeutic strategies

Regenerative Medicine ◽

10.2217/rme-2021-0069 ◽

2021 ◽

Author(s):

Lianxu Cui ◽

Yasmeen Saeed ◽

Haomin Li ◽

Jingli Yang

Keyword(s):

Traumatic Brain Injury ◽

Stem Cells ◽

Stem Cell ◽

Brain Injury ◽

Regenerative Medicine ◽

Cell Therapy ◽

Therapeutic Strategies ◽

Study Data ◽

Health Concern ◽

Standardized Treatment

Traumatic brain injury (TBI) is a serious health concern, yet there is a lack of standardized treatment to combat its long-lasting effects. The objective of the present study was to provide an overview of the limitation of conventional stem cell therapy in the treatment of TBI and to discuss the application of novel acellular therapies and their advanced strategies to enhance the efficacy of stem cells derived therapies in the light of published study data. Moreover, we also discussed the factor to optimize the therapeutic efficiency of stem cell-derived acellular therapy by overcoming the challenges for its clinical translation. Hence, we concluded that acellular therapy possesses the potential to bring a breakthrough in the field of regenerative medicine to treat TBI.

Download Full-text